Pharmacogenomics of Mood Stabilizers in the Treatment of Bipolar Disorder. (13th July 2010)

• Record Type: Journal Article
• Authors: Squassina, Alessio; Manchia, Mirko; Del Zompo, Maria
• Other Names: Nilsson M. Academic Editor.
• Is Part Of: Human genomics and proteomics. Volume 2010(2010)
• Publication Date: 2010-07-13
• Subjects: Human genome -- Periodicals; Genomics -- Periodicals; Genetics -- Research -- Periodicals; Pharmacogenetics -- Periodicals; Proteomics -- Periodicals; Proteins -- Periodicals; 611.01816
• DOI: 10.4061/2010/159761
• Languages: English
• ISSNs: 1757-4242

Abstract

Abstract : Bipolar disorder (BD) is a chronic and often severe psychiatric illness characterized by manic and depressive episodes. Among the most effective treatments, mood stabilizers represent the keystone in acute mania, depression, and maintenance treatment of BD. However, treatment response is a highly heterogeneous trait, thus emphasizing the need for a structured informational framework of phenotypic and genetic predictors. In this paper, we present the current state of pharmacogenomic research on long-term treatment in BD, specifically focusing on mood stabilizers. While the results provided so far support the key role of genetic factors in modulating the response phenotype, strong evidence for genetic predictors is still lacking. In order to facilitate implementation of pharmacogenomics into clinical settings (i.e., the creation of personalized therapy), further research efforts are needed.